These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26140382)

  • 1. Mucosal and systemic immune responses induced by a single time vaccination strategy in mice.
    González Aznar E; Romeu B; Lastre M; Zayas C; Cuello M; Cabrera O; Valdez Y; Fariñas M; Pérez O
    Can J Microbiol; 2015 Aug; 61(8):531-8. PubMed ID: 26140382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1.
    Romeu B; González E; Del Campo J; Acevedo R; Zayas C; Valdés Y; Cabrera O; Cuello M; Balboa J; Lastre M; Pérez O
    Can J Microbiol; 2011 Mar; 57(3):256-61. PubMed ID: 21358768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal and sublingual delivery of inactivated polio vaccine.
    Kraan H; Soema P; Amorij JP; Kersten G
    Vaccine; 2017 May; 35(20):2647-2653. PubMed ID: 28400164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses.
    Gallorini S; Taccone M; Bonci A; Nardelli F; Casini D; Bonificio A; Kommareddy S; Bertholet S; O'Hagan DT; Baudner BC
    Vaccine; 2014 Apr; 32(20):2382-8. PubMed ID: 24434044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice.
    Buffa V; Klein K; Fischetti L; Shattock RJ
    PLoS One; 2012; 7(12):e50529. PubMed ID: 23272062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteliposome-derived Cochleate as an immunomodulator for nasal vaccine.
    Pérez O; Bracho G; Lastre M; Zayas C; González D; Gil D; del Campo J; Acevedo R; Taboada C; Rodríguez T; Fajardo ME; Sierra G; Campa C; Mora N; Barberá R; Solís RL
    Vaccine; 2006 Apr; 24 Suppl 2():S2-52-3. PubMed ID: 16823925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avian reovirus sigma C enhances the mucosal and systemic immune responses elicited by antigen-conjugated lactic acid bacteria.
    Lin KH; Hsu AP; Shien JH; Chang TJ; Liao JW; Chen JR; Lin CF; Hsu WL
    Vaccine; 2012 Jul; 30(33):5019-29. PubMed ID: 22531554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid.
    Westerink MA; Smithson SL; Srivastava N; Blonder J; Coeshott C; Rosenthal GJ
    Vaccine; 2001 Dec; 20(5-6):711-23. PubMed ID: 11738734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nasal aluminum (oxy)hydroxide enables adsorbed antigens to induce specific systemic and mucosal immune responses.
    Xu H; Ruwona TB; Thakkar SG; Chen Y; Zeng M; Cui Z
    Hum Vaccin Immunother; 2017 Nov; 13(11):2688-2694. PubMed ID: 28933668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diversity of mucosal immune responses in upper respiratory organs and its application for mucosal vaccine.
    Kurono Y; Miyashita K; Makise T; Nagano H
    Adv Otorhinolaryngol; 2011; 72():146-8. PubMed ID: 21865715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses.
    Campo JD; Zayas C; Romeu B; Acevedo R; González E; Bracho G; Cuello M; Cabrera O; Balboa J; Lastre M
    Methods; 2009 Dec; 49(4):301-8. PubMed ID: 19410000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.
    Sun X; Zhang H; Xu S; Shi L; Dong J; Gao D; Chen Y; Feng H
    Virol J; 2017 Aug; 14(1):163. PubMed ID: 28830557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with Single Oral Dose of Alginate-Encapsulated BCG Elicits Effective and Long-Lasting Mucosal Immune Responses.
    Hosseini M; Dobakhti F; Pakzad SR; Ajdary S
    Scand J Immunol; 2015 Dec; 82(6):489-97. PubMed ID: 26286252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes.
    Wang T; Yin H; Li Y; Zhao L; Sun X; Cong H
    Parasite; 2017; 24():12. PubMed ID: 28367800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
    Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
    Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
    Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA
    Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights in mucosal vaccine development.
    Pavot V; Rochereau N; Genin C; Verrier B; Paul S
    Vaccine; 2012 Jan; 30(2):142-54. PubMed ID: 22085556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.